322 results on '"Weroha, S. John"'
Search Results
2. Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents
3. Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
4. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer
5. Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors
6. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
7. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair
8. A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
9. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
10. Targeting an autocrine IL-6–SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma
11. Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing
12. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting
13. Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
14. Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
15. Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
16. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis
17. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts
18. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers
19. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
20. Senolytics improve physical function and increase lifespan in old age
21. Supplementary Materials, Figure S1-S4, Table S1-S9 from Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C
22. Data from Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C
23. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
24. Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
25. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts
26. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C
27. Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile
28. Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling
29. Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
30. Data from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
31. Supplementary Figures 1-8 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
32. Supplementary Materials and Methods from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
33. Data from GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
34. Supplementary Figures S1, Tables S1-S2 from GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
35. Supplementary Figure 1 from Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth
36. Supplementary Figure Legend from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
37. Supplementary Tables from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
38. Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
39. Supplementary Methods and oligonucleotide sequences from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents
40. Data from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents
41. Supplementary Information from Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion
42. Supplementary Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
43. Figure S3 from Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion
44. Supplementary Figures S1-6. from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents
45. Supplementary Table 2 from Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments
46. Supplementary Figures 1 - 4 from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
47. Supplementary Table 1 from Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments
48. S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
49. Data from Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer
50. Supplementary Data from Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.